PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate ...

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Associate (CRA) ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

ACD440 is a topical gel formulation targeting peripheral neuropathic pain. The substance, a TRPV1 antagonist, shows powerful ...